We are pleased to announce that we have raised a total of 2,375 million JPY through a third-party allotment of new shares to SIIX Corporation (Headquarters: Chuo-ku, Osaka; President and CEO: Koji Yanase).
Building on this capital raise, we will invest in preparations for the launch of our manufacturing site to establish an integrated manufacturing system for antibody drugs, thereby building our production capacity. We aim to realize our vision of an “Advanced Biomanufacturing Factory” and grow as a CDMO capable of delivering value in the manufacturing of antibody drugs.